NexImmune, Inc. (NEXI)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -29.19 Million USD | 53.72% |
| 2022 | -63.08 Million USD | -18.45% |
| 2021 | -53.25 Million USD | -91.21% |
| 2020 | -27.85 Million USD | -33.35% |
| 2019 | -20.88 Million USD | -57.71% |
| 2018 | -13.24 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -3.5 Billion USD | -27.27% |
| 2024 Q1 | -2.75 Million USD | 48.63% |
| 2023 Q4 | -5.36 Million USD | 46.3% |
| 2023 Q3 | -9.99 Million USD | -28.4% |
| 2023 Q1 | -9.82 Million USD | 43.03% |
| 2023 Q2 | -7.78 Million USD | 20.77% |
| 2023 FY | -29.19 Million USD | 53.72% |
| 2022 Q3 | -14.85 Million USD | 6.72% |
| 2022 Q2 | -15.92 Million USD | -5.8% |
| 2022 Q1 | -15.05 Million USD | 3.08% |
| 2022 FY | -63.08 Million USD | -18.45% |
| 2022 Q4 | -17.24 Million USD | -16.1% |
| 2021 Q1 | -10.07 Million USD | -42.82% |
| 2021 FY | -53.25 Million USD | -91.21% |
| 2021 Q4 | -15.53 Million USD | -0.27% |
| 2021 Q3 | -15.49 Million USD | -27.36% |
| 2021 Q2 | -12.16 Million USD | -20.78% |
| 2020 Q2 | -6.77 Million USD | -6.51% |
| 2020 Q1 | -6.36 Million USD | -23.08% |
| 2020 FY | -27.85 Million USD | -33.35% |
| 2020 Q4 | -7.05 Million USD | 8.02% |
| 2020 Q3 | -7.66 Million USD | -13.15% |
| 2019 Q4 | -5.16 Million USD | 0.0% |
| 2019 FY | -20.88 Million USD | -57.71% |
| 2018 FY | -13.24 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| America Great Health | -492.64 Thousand USD | -5825.675% |
| Ampio Pharmaceuticals, Inc. | -9.51 Million USD | -206.708% |
| Aridis Pharmaceuticals, Inc. | -29.99 Million USD | 2.669% |
| Biora Therapeutics, Inc. | -67.14 Million USD | 56.522% |
| Bio-Path Holdings, Inc. | -15.84 Million USD | -84.261% |
| Better Therapeutics, Inc. | -38.26 Million USD | 23.704% |
| Calithera Biosciences, Inc. | -42.07 Million USD | 30.616% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | -143.88% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.84 Million USD | 13.744% |
| Eloxx Pharmaceuticals, Inc. | -34.41 Million USD | 15.185% |
| Evelo Biosciences, Inc. | -108.46 Million USD | 73.086% |
| Evolutionary Genomics, Inc. | -2.01 Million USD | -1349.26% |
| Finch Therapeutics Group, Inc. | -34 Million USD | 14.145% |
| Galera Therapeutics, Inc. | -46.95 Million USD | 37.824% |
| Innovation1 Biotech Inc. | -1.36 Million USD | -2034.911% |
| Kiromic BioPharma, Inc. | -19.93 Million USD | -46.407% |
| Molecular Templates, Inc. | -10.46 Million USD | -178.927% |
| Navidea Biopharmaceuticals, Inc. | -14.05 Million USD | -107.762% |
| Orgenesis Inc. | -53.63 Million USD | 45.573% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 43.088% |
| Point of Care Nano-Technology, Inc. | -78.01 Thousand USD | -37318.101% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | -80.811% |
| Scopus BioPharma Inc. | -11.71 Million USD | -149.192% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 94.211% |
| Statera Biopharma, Inc. | -98.34 Million USD | 70.316% |
| TRACON Pharmaceuticals, Inc. | -6.89 Million USD | -323.202% |
| Trevena, Inc. | -35.28 Million USD | 17.274% |
| Vaxxinity, Inc. | -58.28 Million USD | 49.914% |
| Vaccinex, Inc. | -22.88 Million USD | -27.562% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | -2688.261% |
| Viracta Therapeutics, Inc. | -50.69 Million USD | 42.413% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -301.934% |